Market research
VIV.V Avivagen Inc
V CAD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 388K
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- Not available
- Beta
- 1.0
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA05382F2026
- Market cap
- 388K
- P/E ratio
- Not available
- Analyst target
- 1.38
- Dividend yield
- Not available
- Beta
- 1.0
About
About Avivagen Inc
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.
Research context
Avivagen Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VIV.V discussion.
5 years, 6 months ago
Avivagen Inc is currently in a long term downtrend where the price is trading 20.2% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.9.
Avivagen Inc's total revenue rose by 5.7% to $262K since the same quarter in the previous year.
Its net income has increased by 4.9% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 64.2% to $-355K since the same quarter in the previous year.
Based on the above factors, Avivagen Inc gets an overall score of 4/5.